Drug Type Small molecule drug |
Synonyms LP 108, LP-108 |
Target |
Action inhibitors |
Mechanism Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC48H55ClN8O7S |
InChIKeyCCDRQWAEZGRMTP-WJOKGBTCSA-N |
CAS Registry2291166-56-6 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Recurrent Chronic Lymphoid Leukemia | Phase 2 | - | 30 Jul 2026 | |
| Diffuse Large B-Cell Lymphoma | Phase 2 | - | 30 May 2026 | |
| Follicular Lymphoma | Phase 2 | - | 30 May 2026 | |
| Mantle-Cell Lymphoma | Phase 2 | - | 30 May 2026 | |
| Waldenstrom Macroglobulinemia | Phase 2 | - | 30 May 2026 | |
| Chronic Lymphocytic Leukemia | Phase 2 | China | 18 May 2026 | |
| Small Lymphocytic Lymphoma | Phase 2 | China | 18 May 2026 | |
| Mature B-Cell Neoplasm | Phase 2 | China | 14 May 2026 | |
| Acute Myeloid Leukemia | Phase 1 | United States | 06 Jul 2020 | |
| Acute Myeloid Leukemia | Phase 1 | China | 06 Jul 2020 |
NCT04356846 (EHA2024) Manual | Phase 1 | 33 | LP-108 at dose levels from 20 mg/day to 800 mg/day | zbyvxrlbfe(qcfhrmgiwc) = sodqfsfvju arjjcmskgs (fxktziqupm ) View more | Positive | 14 May 2024 | |
Phase 1 | 32 | mbulxdtygk(zuxdzfxfeb) = qopiqmdbyn sapnukzmeu (wsqxsmxvfb ) View more | - | 08 Jun 2023 | |||
mbulxdtygk(zuxdzfxfeb) = fqxwnkpcdw sapnukzmeu (wsqxsmxvfb ) View more | |||||||
Phase 1 | 49 | pfgqicaawn(yduyrgtpgc) = imlxrpgjfj tgfgrwchxs (xkbkdtiekv ) View more | - | 08 Jun 2023 | |||
NCT04356846 (EHA2022) Manual | Phase 1 | 19 | mzhjldubkd(vajkywhqmk) = ngjfkgnzdh zdsqqrqdwu (knrcnmrznr ) View more | Positive | 12 May 2022 |





